FDA grants priority review for Enspryng in rare disease MOGAD
Roche's drug candidate gets expedited FDA review for treating rare neurological disorder.
1FDA Priority Review Status
The U.S. Food and Drug Administration has granted priority review to Enspryng (satralizumab) for the treatment of MOG antibody-associated disease (MOGAD). This designation means the FDA aims to take action on the application within 6 months, compared to the standard 10-month review period. Priority review is granted to drugs that may offer significant improvements in safety or effectiveness for serious conditions. The decision date is set for Q1 2024.
2About MOGAD
MOG antibody-associated disease is a rare neurological disorder where the immune system attacks myelin oligodendrocyte glycoprotein (MOG) in the central nervous system. It can cause optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis. The condition affects approximately 1-2 per 100,000 people globally. Current treatments are limited to off-label use of immunosuppressants, creating significant unmet medical need for approved therapies.
3Enspryng's Mechanism
Enspryng is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. By inhibiting IL-6 signaling, it may reduce inflammation in MOGAD. The drug is already approved for neuromyelitis optica spectrum disorder (NMOSD) in multiple countries. Clinical trials showed it reduced relapse risk by 55% in NMOSD patients. Roche is now seeking to expand its indication to include MOGAD.
4Clinical Trial Results
The application is based on Phase 3 SAkuraStar trial data showing Enspryng's efficacy in MOGAD. Patients treated with satralizumab experienced 74% fewer relapses compared to placebo. The drug demonstrated a favorable safety profile consistent with its established use in NMOSD. These results were published in The Lancet Neurology in 2022. Roche has also completed a pediatric study for MOGAD.
5Market Potential
Analysts project the MOGAD treatment market could reach $500 million annually by 2027. Enspryng currently generates about $200 million yearly from NMOSD sales. Approval in MOGAD could add $150-300 million in peak sales. Roche faces competition from Horizon Therapeutics' Uplizna and Alexion's Soliris, though neither is specifically approved for MOGAD. The priority review could give Roche first-mover advantage.
6Regulatory Strategy
Roche is pursuing MOGAD approval under the FDA's 505(b)(2) pathway, which allows reliance on previous findings for NMOSD. This strategy accelerates development by reducing required clinical trials. The company has also secured orphan drug designation, providing 7 years market exclusivity if approved. European and Japanese regulatory submissions are expected to follow the FDA decision.
7Patient Access Considerations
As a biologic, Enspryng's list price exceeds $100,000 annually, raising access challenges. Roche has patient assistance programs that reduce costs for eligible individuals. The company is working with insurers to establish coverage policies ahead of potential approval. Patient advocacy groups have been actively involved in trial recruitment and raising disease awareness.
8Broader Implications
This review represents growing recognition of MOGAD as distinct from other neuroinflammatory disorders. Success could spur research into other rare autoimmune diseases of the central nervous system. The expedited review also demonstrates FDA's commitment to addressing unmet needs in rare diseases. Approval would establish IL-6 inhibition as a validated approach for MOGAD treatment.
Original article: All News — FDA grants priority review for Enspryng in rare disease MOGAD